Life long Maverick: Seen it ALLl in 40 yrs of PROF. exposure as invest analyst/port mgr on the FRONT lines vs iHub Msg Bds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Re Shrewd, Devilish SNAKE (Pyrrh/MedRes m: just noticed iHub Suspension etc)
I am just getting slightly caught up with FAST changing post developments since early June!
To correct the WRONG perception here of the above character of being Short @$3:
As I stated many months ago, and perhaps it was misread/overlooked with all that has ensued:
Steve G. plies the emerging biotech sector largely for issues that have PUT Options so his exposure is just what he laid out vs what has been possibly misperceived: Short since $3.
I do have an extensive file beyond what’s been disclosed. Went to such lengths due to the morality and ethics as a vigilante good citizen to expose him and many others like him BEFORE anybody was even aware of his SNAKY actions: nothing personal.
Despite Steve G’s legal lawsuit threats he sent me!......It did not intimidate; worry; let alone deter me! In spite of scores of post removals!
DIFFERENT STROKES FOR DIFFERENT FOLKS
iwasadiver re:
5 Signs of Unhealthy Gut and Tips to Improve Gut Health
Oscar Shepherd
North40000: Instead of Outdated should have used Superseded.
Bottomline no change in views as Big mfrs of EV’s and today’s hi tech consumer devices of Lithium ion batteries are clearly transitioning away from high cost cobalt to that of nickel and developing solid state ones which are the holy grail. Those views are not just trade experts but from the Real Movers & Shakers
Those WSJ articles cited are “small “ having no investment significance IMHO as they do not consider the interplay of Real Dynamics of Technological Substitutes re timely use/cost benefit analysis.
Mining for Critical Rare Earth minerals is a long expensive process especially for Cobalt as it is a by product of Copper and Nickel finds.
DIFFERENT STROKES FOR DIFFERENT FOLKS
12 of the best brain foods.
1. Oily fish
oily fish canned tuna in a bowl.
Oily fish contains omega-3 that can help boost brain health.
Oily fish are a good source of omega-3 fatty acids. Omega-3s help build membranes around each cell in the body, including the brain cells. They can, therefore, improve the structure of brain cells called neurons.
A 2017 study found that people with high levels of omega-3s had increased blood flow in the brain. The researchers also identified a connection between omega-3 levels and better cognition, or thinking abilities.
These results suggest that eating foods rich in omega-3s, such as oily fish, may boost brain function.
Examples of oily fish that contain high levels of omega-3s include:
salmon
mackerel
tuna
herring
sardines
People can also get omega-3s from soybeans, nuts, flaxseed, and other seeds
https:/www.medicalnewstoday.com/articles/324044.php
DIFFERENT STROKES FOR DIFFERENT FOLKS
North400 re:
To be a successful investor one needs to be AHEAD of the CURVE AND still in that upcoming environment still be ON the rails!
The above takes many skillsets and few can grapple with in a lifetime given the ultra dynamics of the world we live in: ie Global Warming/Climate Change
Re Crop Yields; Islands disappearing; cities/homes under water etc etc.
Specifically it all relates to understanding how each investment may avoid the above potential exposureS and how each is strategically positioned to withstand the impending onslaughts. Some may need a back up plan. Clearly that’s what supposedly why CEO’s get paid multiple scores above average Corp employees!
Taking BOTH a bottom’s up analysis as well as a top down analysis is the optimal
One clearly needs to understand as it relates to ANY company one cited:
Will they be #1 or # 2 in their respective fields and IF they are not currently what do they need to get to topple those incumbents?
Will consumers still be buying in that environment?
Is the technology far superior?
Where are each company in terms of the products life cycle: I stated two years ago in many posts the
Saturation of Smartphones and Apple’s tough slough in China
LOTS of spadework
Fortunately AMRN’s Vascepa is well positioned as there is an INELASTIC demand for their proprietary compound which I discovered on my own four years ago in surfing thru for the first and only time the FDA’s database that convinced me that Vascepa is a NCE: more than doubled up at ~$1!
DIFFERENT STROKES FOR DIFFERENT FOLKS
I have never considered to get to that level of granularity as my main mantra is strategic.
BTW NO Wall St professional ever would parse that!
There are clearly so many more important issues for aMoney Mgr to deal with such as what Ray Dalio interviewed today: World is embarking into a replay of late 1930’s! that surprisingly I share as well!
Another example that speaks to entering a STAGFLATION WW economic environment:
Nickel used in stainless steel and even in lithium ion batteries.... nickel prices up YTD +68%!!
Indonesia a large nickel producer announced TODAY
a ban on nickel exports starting in Dec!
Larry Summers w/in last week had an Op-Ed highlightingthat the world’s central bankers ARE at their limit and do not have sufficient reserve to deal with a downturn!
DIFFERENT STROKES FOR DIFFERENT FOLKS
Understand! and nothing to do with analyst’s price targets
Those who were adamant of well beyond $50/ ie BB; Marzan etc when too many were overly Ebullient to the point of either or BOTH doing call options and using their Margin Buying Power:
When I get a chance will post those pageS highlighting the above!
NONE of that IMHO was a wise move as history has demonstrated!
That was WHEN the shares were $22 plus : wasn’t that long ago:
June??
ALL of the above was the view I harborED but did NOT want to post
Can’t deal with Tidal Waves!
Thanks North4000 for your reply.
DIFFERENT STROKES
Perceptive observation and fully agree!
That’s why I detest emerging biotechs with OPTIONS that can cause periodic havoc in the absence of a positive catalyst. ( see my comments in last 14 hrs).
Been noticing (when I have found the time) this that you have become a welcome value added addition
counter balancing this board.
All one can do is not go to the edge with MARGIN! let alone OPTIONS!
Inst’l players are here for the long haul and have the pockets to ride it out: DO YOU??? Doesn’t look like it with so much of the board’s posts related to short term Option activity!
The board has been TOO TRANSPARENT with their Stratospheric Valuation targets AND sophisticated deep pocketed players have been TESTING the Short term financial resolve of AMRN shareholders for the last many months AND taking advantage of it!!
DIFFERENT STROKES FOR DIFFERENT FOLKS
Hi JL:
Hopefully you have this in the PROPER context:
Evercore/ISI Group is a powerhouse in the Institutional side of the business period.
Obviously JT has been involved with Evercore since that fortuitous post as JT has made presentations there.
What really perturbs me is the allegation that Evercore is behind the Put Options. Is Evercore a CBOE licensed Option mktmkr??
Only extremely deep pocketed firms
with the infrastructure can do this:
I’m no expert but 5 yrs ago I delved into it to due to Susquehanna Holdings(MAJOR GOOG MSFT etc Options MktMkr started up by IT Drexel Univ grads!!) being an NWBO shareholder. Was an eye opener!
Just did some fast spadework: maybe incomplete: I don’t see Evercore as a CBOE licensed Option maker for AMRN : just GROUP ONE!
http://www.cboe.com/trading-resources/symbol-directory/equity-index-leaps-options
IF Evercore then they are only executing as a MIDDLEMAN for their customers no different than that of say a Goldman
So unless someone could demonstrate with a link it’s false:
Evercore has INTEGRITY unlike Goldman re decades of articles about Goldman!
Hope that puts the right perspective on this matter.
Hoping your health IMPROVES:
I have found some invaluable articles that I will post for the AMRN community that I have practiced since 1990: the last time I saw a doctor was 1985; have not spent a penny on health care since 1985!
I am now 70 yrs old and still look like my posted picture and just beginning to have some sideburn gray hairs; I could actually fit the same business suits I wore in my twenties where I was suited by the founder of Barney’s (Barney Pressman) going thru their 4th? Bankruptcy proceeding.
DIFFERENT STROKES FOR DIFFERENT FOLKS
How does Evercore even come up logically as Evercore is an Institutional Broker.( middleman)
It’s the option player owner( hedge fund)
Does the CBOE have periodical public listing by security by owner.
CalMustang that info would be valuable IMHO for AMRN corp to track down or even your previous Baker Bros contact re Steve G (Pyrrh) may? provide or at least confirm it exists! for purchase?
DIFFERENT STROKES FOR DIFFERENT FOLKS
Notice that Inst’l Investor ALL Star Team List is only done annually: that was Fall 2018! the latest available AFAIK.
BTW another clue of Evercore’s stature in Biotech is the recent death of:
Obituary
Former Star Biotech Analyst Mark Schoenebaum, 46, Has Died
By Drew Armstrong
August 26, 2019, 8:37 AM EDT
Updated on August 26, 2019, 4:41 PM EDT
Mark Schoenebaum, the former star biotechnology analyst at Evercore ISI known for his rapid-fire assessments of the sector, has died. He was 46.
Schoenebaum died over the weekend in New York, according to a colleague. The cause of death wasn’t specified.
Mark Schoenebaum
Mark SchoenebaumSource: Evercore
Schoenebaum spent almost two decades on Wall Street as a biotechnology and pharmaceutical analyst. He was ranked as Institutional Investor Magazine’s top biotechnology analyst for more than a decade, according to his LinkedIn profile. He took a medical leave from Evercore in 2016, returning to the New York-based company for three months before taking a second leave of absence in March 2017, and then leaving the firm.
“We’ve all looked up to him as the very best equity research analyst there has ever been on Wall Street,” Umer Raffat, Schoenebaum’s former colleague at Evercore, said in an email. “But that was only part of who he was: He was an absolute standout individual who touched so many lives, and whose strength of character showed in his sheer humility despite his absolutely unprecedented success.”
Schoenebaum graduated from the Johns Hopkins School of Medicine in 2000 and began a career on Wall Street soon after. Following stints at Piper Jaffray Cos., Bear Stearns & Co. and Deutsche Bank AG, he joined Evercore in 2010.
“Mark was an extraordinary analyst, a great thinker, great writer, and a great communicator,” Evercore ISI Chairman Ed Hyman said in an emailed statement. “We will be always be thankful for his many contributions.”
Born in Des Moines, Iowa, Schoenebaum often made reference to his Midwestern upbringing in video messages assessing the industry. He was also an accomplished violinist.
Schoenebaum and his wife, Tiffany Tedore, an anesthesiologist at New York Presbyterian Hospital and a faculty member at Weill Cornell Medical College, had two children: Isadora and Lucille.
————————————-//
These two analysts, have in short order, remarkably filled his shoes:
Umer Raffat Biotechnology/Large-Cap
Josh Schimmer Biotechnology/Mid- & Small-Cap
So who has documented info to back up DanfromChicago that Evercore”slipped”?
Until there is credible validation, here say!
BTW another INACCURACY:
I was never in IBK re Merger/Acquisition.
I was a portfolio mgr/analyst working at Sanford Bernstein; MerrillLynch; Cowen.
I have not sold a share, never on margin, do not play options since 1977!
Did everyone see that Bloomberg article citing Goldman is spending $100 mln to develop software to shave milliseconds from a trade!
The use of Algorithms in tracking retail trading whether in stocks or options makes it HARD to beat the widening use of sophisticated IT. Inst’l hedge funds have lots at their disposal to outwit retail shareholders.
I rarely have short posts: FULL DISCLOSURE unlike most: drips and drabs too time consuming
DIFFERENT STROKES FOR DIFFERENT FOLKS
Rarely visit this site lately but by chance noticed this mentioning me by name.
To really clear the air here this is EXACTLY what I stated versus being jumbled and incorrect:
Monday, 11/19/18 09:14:26 PM
Re: None 0
Post # of 211848
JL/Ilovetech: MARKETING Initiation/Coverage by TOP ranked Evercore ISI Group's two top analysts in Biotechnology would get the shares UP:
BOTH of these are the TOP RATED ANALYST in Biotechology as surveyed (Fall 2018) in the well respected Annual Institutional INvestor Research Surveys:
Umer Raffat Biotechnology/Large-Cap
Josh Schimmer Biotechnology/Mid- & Small-Cap
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
Evercore was started by Roger Altman: https://en.wikipedia.org/wiki/Roger_Altman
that combined with NYC famed ISI Group started by Ed Hyman who I met at a luncheon in the late 1980's:
https://www.bloomberg.com/opinion/articles/2015-06-30/ed-hyman-the-best-strategist-you-ve-never-heard-of
A few of my bosses and fellow analysts were on this All Star Research Analysts list.
This is the TRADE Publication for Wall Street and has been around since at least 1970.
https://www.prnewswire.com/news-releases/evercore-isi-recognized-as-the-top-ranked-independent-firm-in-us-equity-research-300728143.html
So if JL or Ilovetech's brother could mention that to IR dept and/or CEO John Thero! that would significantly add to the Institutional Ownership and get us on the way.
First the Avalanche of VASCEPA Scripts ALONG WITH high calibre and wider Wall St coverage a ONE TWO COMBO KNOCKOUT TKO!.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Thanks Kabunushi for sharing your Innes conversation re redefining dated UCLA’s Direct and CI studies:
It makes imminent sense as so much has occurred since then!
Wouldn’t want them to undergo that of DCVAX L!
BTW: For the record in my 5 yrs here; have yet to feel a need to speak to NWBO. That one time was as posted giving NWBO guidance.
DIFFERENT STROKES FIR DIFFERENT FOLKS
Doc_Logic re:
I wholeheartedly agree and I would even suggest that Cognate's CEO strongly pointed to just such a link by telling us all to "stay tuned" which is, of course, is the Linda Powers mantra. So glad someone hete has taken that mantra to heart and kept us posted. Best wishes.
Phase 2: more new Blood Transfusions in NWBO Program OutReach:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150817462
DIFFERENT STROKES FOR DIFFERENT FOLKS
FDA's Dr. Norman (Ned) Sharpless: re deadliest cancer: GBM; Acceptance Speech, NWBO
1) youtube on GBM Awareness Day July 17, 2019
I was really elated to be invited to this. This is really a personal effort to me. I would really love to see some progress in GBM. Probably no cancer pisses me off more than GBM. You know it would be great to relieve it.the FDA has been committing to putting all hands on deck approach to supporting drug and device development aimed at treating patients with GBM.The FDA also has several methods to streamline and fast-track review of investigational therapies for a lot of life threatening orphan diseases, and I can think of no better candidate for those kinds of mechanisms than GBM. These include the break-though therapy designation, fast-track review, priority review,and programs designed to move the products through the review process rapidly, as well as accelerated approval where drugs are allowed onto the market based on the activity at certain end points
We’re hopeful that progress will be made in this disease as multiple new technologies are brought to bear on this problem, the new exciting immunotherapies, some new targeted therapies, new types of careful clinical trials with adaptive design and novel to better find agents more quickly and the better use of radiation therapy, surgery, novel devices, imaging, and other therapeutic approaches in this space
An estimated 700,000 Americans are living with a brain tumor
69.1% tumors are benign
30.1% tumors are malignant
An estimated 86,970 people will receive a primary brain tumor diagnosis in 2019
60,800 will be benign
26,170 will be malignant
My Plans at FDA
I am sure many of you would like to know specifically what I plan to do as Acting FDA Commissioner.
In the coming weeks, I will be highlighting some of my public health priorities, but let me make a few general points today.
First, I am a great admirer of Dr. Gottlieb. Scott and I had long discussions about much of the business before the FDA, and he gave me great advice.
There will of course be some letup from Gottlieb: for example, I don’t have nearly as interesting socks from a wardrobe POV.
On the plus side, I am pretty sure I can beat his time in the FDA 5K coming up this May 3 (since I am told he never ran it). In fact, I am planning on setting the Commissioner’s Record.
And let me dispel any misconceptions that the change in leadership reflects some desire of the President or the Secretary for the FDA to go in a different direction from the Gottlieb era.
That is not the case, Secretary Azar and the White House have been very clear with me that they have been impressed with the FDA’s efforts and would like to see this strong progress continue.
Moreover, there is great support for the FDA’s mission in Congress. This support is positive and bipartisan.
I’ve already experienced this first hand through a number of calls with key legislators and they’ve confirmed the high regard with which Congress holds the FDA.
So let me reassure you, I am not planning any radical changes from what the FDA has been trying to accomplish.
Woodford ends painful Prothena journey with £50m sale
By Daniel Grote 28 Aug, 2019 at 11:40
5 Comments
Woodford ends painful Prothena journey with £50m sale
Embattled fund manager Neil Woodford has sold his stake in Prothena (PRTA.O), the biotech stock whose share price plunge last year delivered one of the biggest blows to his funds.
Woodford raised around £50 million through the sale of his remaining stake in the Irish Nasdaq-listed company from his suspended £3.1 billion Woodford Equity Income fund and smaller Woodford Income Focus.
San Francisco biotech investor EcoR1 Capital snapped up the stake on Friday, according to filings with the US Securities and Exchange Commission.
Shares in Prothena rallied 26% on the news, as investors welcomed the removal of the large overhang of Woodford's holding in the company, which amounted to 22% of the shares.
The sale ends Woodford's painful journey in holding the stock, which featured in his original portfolio when launching Woodford Equity Income in 2014 and was the top holding when his Woodford Patient Capital (WPCT) investment trust launched the following year.
Woodford steadily built his position in the stock, which was among the biggest contributors to his flagship fund's strong run in its first two years.
Around its peak, Woodford's stake in the company, held across all three of his funds, was worth approximately £550 million, as investors sent the shares higher on hopes for Prothena's drug to treat the rare amyloidosis disease.
The stock grew to a position of more than 16% of Woodford Patient Capital's assets, and also featured in the top 10 of Woodford Equity Income.
But Prothena came crashing down in April last year, tumbling 70% in a single day after a test failure for its key amyloidosis treatment.
SEC filings suggest Woodford Patient Capital had sold its stake in Prothena, which accounted for 2.1% of the trust's assets at the end of last year, by the end of June. That sale is likely to have raised around £20 million.(From a 550 UK pd investment in Prothena to a 530 UK lb LOSS!: a 96% LOSS; ON NWBO Woodford Funds invested ~$190 mln and LOST ~$185 mln or another 97% LOSS!)
Woodford's offloading of his Prothena stake takes the amount raised from stock sales across his three funds since the suspension of Woodford Equity Income to around £900 million.
The bulk of that has been raised from disposals in his flagship, suspended fund, with the manager investing around 80% of the proceeds into FTSE 100 stocks.
Three months after the suspension, how is Woodford Equity Income getting on?
The fund has continued to suffer from specific stock-related issues.
Funds and Investment Trusts August 27, 2019 by Tom Bailey
It is almost three months since star fund manager Neil Woodford took the decision to temporarily suspend trading of his flagship Woodford Equity Income fund.
The decision was not greeted kindly. Woodford himself has come under fire for choosing to fill his portfolio with relatively illiquid stocks, creating a liquidity mismatch, which forced the fund to suspend trading. As a result, regulators have become increasingly concerned about the liquidity open-ended funds promise.
Woodford’s reputation as a fund manager has also taken a blow. First, Woodford has continued to come under fire for continuing to charge investors in the suspended fund management fees. At the same time, the fund manager’s reputation as a skilled stockpicker has been dented.
Woodford, however, promises to fight on. In the latest update from the Link Fund Solutions, the authorised corporate director of the fund, Woodford Equity Income is expected to be on track to re-open in December, once the fund has been rebalanced to more liquid stocks.
According to the statement from Link: “Based on the progress made to date, [we] remain of the view that this is a realistic timeframe and therefore have decided that it remains in the interests of all investors for the suspension of dealings to continue.”
Three months into its suspension (and with supposedly three months left until it re-opens), how has the fund performed?
According to data from FE Trustnet, out of 262 funds in IA UK all companies sector – LF Woodford Equity Income the worst performer between 3 June and 23 August. Over the period, the fund lost investors 11.2%, compared to a sector average return of 0.37%.
According to Adrian Lowcock, head of personal investing at Willis Owen, the poor performance is to be expected. He says: “The challenge he faces is huge and the market backdrop hasn’t helped.”
On the one hand, Lowcock points out, trading costs incurred by Woodford’s rebalancing will be eating into returns.
At the same time, the fund has continued to suffer from specific stock-related issues. For example, one of Woodford’s largest holdings, Burford Capital, saw significant damage to its share price after US investment company Muddy Waters put out a very critical note.
More recently, Industrial Heat’s valuation has taken a hit, while Eddie Stobart has suspended trading. Other holdings such as Kier Group have seen profit warnings.
However, says Lowcock, “stock-specific issues are nothing new to Woodford and reflect how the fund was positioned before its suspension with some higher risk investments and a very domestic focus”.
He adds: “With Brexit uncertainty continuing and the unlisted element having risen recently it will be a challenge for Woodford to complete the repositioning by December”.
Woodford’s fund, however, was far from the only fund in the sector with negative returns. Other poor performers included ASI UK Recovery Equity (-7.7%), ASI UK Opportunities Equity (-6.4%), L&G UK Alpha (-5.5%) and JOHCM UK Growth (-5.1%).
Among the best performers over the time period were Royal London Sustainable Leaders (+7.6%), Thesis TM Sanditon (+7.6%), Threadneedle UK Growth & Income (6.8%), Lindsell Train UK Equity (+6%) and Evenlode Income (+5.7%).
Woodford Equity Income fund was also not the only of Woodford’s funds to take a knock. LF Woodford Income Focus was the worst performer in IA UK Equity Income over same time period – down 9.57%. The sector’s average return was 0.04%.
Have you delved into the NPR link I provided:
Higham and his colleagues at the Post were also able to access data from the Drug Enforcement Agency that trace the path of some 76 billion opioid pain pills sold between 2006 and 2012
"A lot of these towns and cities, small cities and counties in places like Ohio and Pennsylvania have just been devastated. ... The death rates just soared in those places where the pills were being dumped."
On the picture emerging from recently unsealed DEA database
Woodford’s Shuttered Fund Crushed Further by Plunging Stocks in its Holdings, such as Muddy-Waters Target Burford Capital
by Nick Corbishley • Aug 26, 2019 • 34 Comments • Email to a friend
Hedge funds have field day front-running the liquidation. 300,000 investors left twisting in the wind.
By Nick Corbishley, for WOLF STREET:
Neil Woodford, the manager of shuttered asset management fund, Woodford Equity Income fund, just had one heck of a black Friday. First came news that Link Fund Solutions, which manages the corporate governance of Mr Woodford’s investment vehicles, had slashed the valuation of cold fusion developer Industrial Heat, one of Woodford’s largest unquoted holdings, by around 40%, from £91.3 million to £55 million.
The move will shave 4.3% off the net asset value of the Woodford Patient Capital (WPCT) investment trust. Having plunged since the suspension of Woodford’s flagship Woodford Equity Income fund (WEI), shares in the trust dropped a further 5.5% on Friday to 41.5p and are now down 46% year to date. Industrial Heat is also held by WEI. Valued at £115 million at the end of December, that stake is now likely to be worth around £70 million, knocking around 1.4% off the fund’s value.
Then came the second blow: another big Woodford holding, British haulage company Eddie Stobart, announced that it was suspending trading in its shares and had fired its CEO after an accounting investigation had found the group’s profits had been overstated. Twenty-three percent of the company’s shares, already down 47% in the last year, belong to Woodford. As long as the shares remain suspended, there’s no way he’ll be able to sell them.
Since deciding to gate WEI on June 3, Woodford has been desperately trying to sell down the fund’s holdings of lightly traded micro-, small- and mid-cap stocks that made up 97% of its assets at the end of May. Small and mid-cap assets can often yield higher returns — between July 2009 and July 2019 the mid-cap dominated FTSE 250 index returned 67% more than the UK’s large-cap index, the FTSE 100 — but they’re also riskier and harder to sell in a hurry, especially if you’re holding a large stake.
Since suspending his flagship fund in early June, Woodford has raised at least £650 million by offloading listed assets held in his frozen flagship fund, according to research by Bloomberg. It’s a step in the right direction but it’s not nearly enough. And every step of the way, hedge funds are one step ahead, mercilessly shorting any listed stock before it’s sold.
A case in point is the litigation funding specialist Burford Capital, which was the second largest holding in Woodford’s gated flagship fund representing 5.8% of total assets at the end of April. Until the beginning of this month, Burford was one of the strongest performing stocks in Woodford’s portfolio, having soared in value more than tenfold in just five years. That was before Muddy Waters Research launched a full-frontal assault on the company’s financial status on Aug 7, since which time Burford has lost around half of its market cap — over £1 billion.
Muddy Waters said that Burford Capital “actively manipulates” its performance metrics and “greatly misleads investors.” It also criticized the company over the fact that its CFO was married to the CEO, a highly irregular situation that has since been remedied with the re-assignment of the CFO.
For its part, Burford accuses Muddy Waters of “illegal market manipulation,” claiming it was victim to “spoofing” and “layering” practices, which are used by sophisticated market players to artificially drive down share prices.
For Woodford, the rout in Burford’s shares has been particularly painful. His stake in the firm, worth £212 million less than a month ago, has since shrunk in value to barely £100 million.
Problems are also mounting for many of Woodford’s healthcare stocks, which account for 23% of his flagship fund. Woodford cut his teeth investing in large healthcare companies for the giant fund manager Invesco, but reinvented himself as a venture backer of early-stage life sciences start-ups when he founding his eponymous firm in 2014. Many of those firms are now struggling, with 16 of the 20 listed healthcare stocks he picked for WEI sharply down in value since the beginning of the year, according to analysis by the London Evening Standard.
Nucana, a UK drugs developer backed by Woodford, is down 48%.
Autolus Therapeutics has fallen nearly 70% this year since announcing a five-month delay in building a critical drug-testing facility.
Verseon has plunged 90% after revealing plans to use blockchain technology to fund drug trials.
Other healthcare stocks such as Circassia Pharmaceuticals, Mereo Biopharma, Prothena, Tissue Regenix and 4D Pharma are down between 20% and 60% so far this year.
Given such dismal results, it’s hardly surprisingly that Bestinvest’s twice yearly “Spot the Dog” report recently crowned Woodford’s troubled Equity Income fund as the UK’s worst-performing fund. When it comes to “dog funds,” Woodford Equity Income fund is “the worst performer of all … managing to turn £100 invested into £80 over the three years assessed,” said Jason Hollands, managing director at Bestinvest.
Since the suspension alone, two months ago, WEI has fallen by 11.2%, compared with a 1.5% gain on its benchmark index, the FTSE All Share Total Return, according to LINK. Woodford Investment Management attributed most of its under-performance in the last seven weeks to the share price decline of Burford Capital and Industrial Heat.
In a letter to investors, Link Fund Solutions assured that the latest target date for reopening Woodford Equity Income fund, early December, “remains achievable”. Woodford Investment says it is reinvesting more than 80% of the proceeds from the sales of WEI’s stakes in FTSE 100 companies, suggesting the fund’s strategy is moving toward liquid, quoted hi-cap stocks, as many investors originally thought was the case.
For the moment, such lofty promises are scant comfort for the more than 300,000 investors whose money is trapped in Woodford’s flagship fund. They know that if the suspension is lifted, what they receive will be less, probably a lot less, than what they put in. And for the time being, there’s no sign of light at the end of the tunnel. By Nick Corbishley, for WOLF STREET.
The exodus from funds with illiquid assets forces more funds to block redemptions. Read… Liquidity Crunch Mangles UK Equity & Real Estate Funds
Enjoy reading WOLF STREET and want to support it? Using ad blockers – I totally get why – but want to support the site? You can donate “beer money.” I appreciate it immensely. Click on the beer mug to find out how:[/quote]
https://wolfstreet.com/2019/08/26/woodfords-shuttered-fund-gets-crushed-further-by-plunging-stock-prices-of-its-holdings-such-as-muddy-waters-target-burford-capital/
NOTE Still do NOT believe based on the previously expressed views by MANY that Woodford's funds have
sold NWBO:
Logical Reasons why it would be NONSENSICAL Woodford has sold. or contemplating selling before yearend::
1)Woodford has till Dec 1st by which time DC VAX L Top Line Data more than likely will be released
2) FDA's Dr. Norman Sharpless graphic GBM July 17th 2019 remarks on keen sense of personal/professional awareness at FDA's OCER of impact of Immuno- oncology and gold standard being OS
3) NOTHING I've seen to justify BOTH of these ridiculous posted comments especially by BSB of:
a) SHORTS have covered!
b) Today BSB reverses his many extreme views (Umibe did that on Monday): BSB posts today that Woodford near done selling NWBO.... hallmarks of trading desk (currency only expertise) hipshot. just like his and Umibe posted comments of unseating CEO Linda Powers. NO SIXTH SENSE for the mindset of CEO Linda Powers because each one of them have been guilty of lacking or over ruling the BASICS of Investment/Portfolio ASSET ALLOCATION DISCIPLINE. That's their Modus Operandi I've witnessed for both. They own a ton of shares yet I have always taken their posts with a grain of salt.
Selling NWBO does NOT amount to much $ at 20 cts
Woodford selling before Dec 1 would be a MONUMENTAL professional confession to 293,000 UK investors of how BAD his DD has been to invest ~$190 million in NWBO. and sell? for ~20 cts for a whopping ~$185 million LOSS? is COLOSSAL
Woodford's Poor Due Diligence as a stock picker??(I have never thought he was ONE!) has been seen in SPADES on lotS of Woodford's holdings. to serve as VALIDATION as profiled in previous posts. Woodford made very poor asset allocation decisions which WAS his PAST decades of glory day records at Invesco..Venturing into specific areas where he did NOT have the expertise has been his DOWNFALL.
That's why without the broad based RELEVANT professional experienced (ONLY BRANKO qualified:
This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq
— Branko Krstevski (@KrstevskiBranko) June 22, 2018
It shows this trial has a real chance of success.
$120M MC with high risk pic.twitter.com/kXGI1SQa7T
Fewer than 10% of glioblastoma patients survive past five years of an initial diagnosis, with most living less than a year. Despite advances in many other cancers, survival rates are getting worse for brain cancer patients, according to the latest Annual Report to the Nation on the Status of Cancer from the National Cancer Institute, CDC, and others. https://seer.cancer.gov/report_to_nation/
The five-year survival rate for GBM patients is only 5.6 percent, and mean survival is estimated at just 12-18 months. These survival rates and mortality statistics for GBM have been virtually unchanged for decades.
QUICK BRAIN TUMOR FACTS
Today, an estimated 700,000 people in the United States are living with a primary brain tumor, and over 86,000 more will be diagnosed in 2019. Brain tumors can be deadly, significantly impact quality of life, and change everything for a patient and their loved ones. They do not discriminate, inflicting men, women, and children of all races and ethnicities.
An estimated 700,000 Americans are living with a brain tumor
69.1% tumors are benign
30.1% tumors are malignant
An estimated 86,970 people will receive a primary brain tumor diagnosis in 2019
60,800 will be benign
26,170 will be malignant
The average survival rate for all malignant brain tumor patients is only 35%
Male: 33.8%
Female: 36.4%
For the most common form of primary malignant brain tumors, glioblastoma multiforme, the five-year relative survival rate is only 5.6%
An estimated 16,830 people will die from malignant brain tumors (brain cancer) in 2019
BRAIN TUMORS IN ADULTS
The most prevalent brain tumor types in adults:
Meningiomas, which make-up 37.1% of all primary brain tumors
Gliomas (such as glioblastoma, ependymomas, astrocytomas, and oligodendrogliomas), which make-up 81% of malignant brain tumors
BRAIN TUMORS IN CHILDREN
More than 28,000 children (0-19 years of age) are estimated to be living with a brain tumor in the US
An estimated 3,720 new cases of childhood (0 – 14) primary malignant and nonmalignant brain and CNS tumors are expected to be diagnosed in 2019
The average survival rate for all primary pediatric (0-19 years of age) malignant brain tumors is 74.1%
Brain and CNS tumors are the most prevalent form of pediatric cancer in kids under 19
Pediatric brain tumors are the leading cause of cancer-related death among children and adolescents ages 0-19, surpassing leukemia.
It is estimated that, in 2009, a total of 47,631.5 years of potential life were lost due to brain tumors in children 0-19 years old
The most prevalent brain tumor types in children (0-14):
Pilocytic Astrocytoma
Malignant Glioma
Medulloblastoma
Neuronal and mixed neuronal-glial tumors
Ependymoma
ADDITIONAL NOTES
The median age at diagnosis is 60
More than any other cancer, brain tumors can have lasting and life-altering physical, cognitive, and psychological impacts on a patient’s life.
This means malignant brain tumors can often be described as equal parts neurological disease and deadly cancer.
Even benign brain tumors can be deadly if they interfere with portions of the brain responsible for vital bodily functions.
There are more than 130 different types of brain tumors, many with their own multitude of subtypes.
Despite the amount of brain tumors, and their devastating prognosis, there have only been four (4) FDA approved drugs – and one device – to treat brain tumors in the past 30 years.
For many tumor types, surgery and radiation remain the standard of care.
There has never been a drug developed and approved specifically for malignant pediatric brain tumors.
The four approved drugs for brain tumors have provided only incremental improvements to patient survival, and mortality rates remain little changed over the past 30 years.
Between 1998 and 2014, there were 78 investigational brain tumor drugs that entered the clinical trial evaluation process. 75 failed. That is a 25:1 failure ratio in developing new brain tumor treatments over the past two decades.[1]
Brain tumors have the highest per-patient initial cost of care for any cancer group, with an annualized mean net costs of care in 2010 US dollars at well over $100,000.[2]
While, there is no official accounting of, and some significant disagreement regarding, the amount of cancer cases each year that metastasize to the brain. Estimates range on the low end from approximately ~56,000 cases to ~500,000 on the high-end of cancer patients developing brain metastases annually.
Studies have cited that the percentage of cancer patients who will develop brain metastases is anywhere from 6-28%.
What we do know is that approximately 80% of cancers have been associated with the ability to metastasize to the brain.
These include, melanoma (where nearly 50% of cases will metastasize to the brain), lung, breast, renal, and colorectal.
***Brain Tumor Facts data collected by Central Brain Tumor Registry of the United States (CBTRUS) in CBTRUS Statistical Facts Report of Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States. (www.cbtrus.org)
[1] “Researching Cancer: Setbacks and Stepping Stones,” PhRMA, 2014
[2] J Natl Cancer Inst. 2011 Jan 19; 103(2): 117–128.
What causes brain tumors? Brain tumor treatment, prognosis and more
Monday Aug 25, 2019 TODAY
Brain tumors come with some of the most life-disrupting symptoms in the human experience: extreme headaches, vertigo, personality changes and balance problems.
They’re also unpredictable, making most anyone vulnerable to a diagnosis.
Sunday marked one year since the death of Sen. John McCain of glioblastoma, an especially aggressive and lethal form of brain cancer.
But even benign brain tumors can be deadly if not treated in time, said Dr. Minesh Mehta, deputy director and chief of radiation oncology at the Miami Cancer Institute.
“The major reason that makes brain tumors dangerous is location, location, location. There is not a portion of the brain that is irrelevant or trivial or useless,” Mehta told TODAY.
“Any tumor in any location of the brain has significant potential for causing some harm to the patient… especially in the context that the brain lives within a closed box — the skull. There’s no place for expansion.”
With so much at stake, it’s important to understand the facts. Here are 10 common brain tumor myths to know about:
1. Cell phones cause brain cancer
Cell phones use low levels of radiofrequency energy. How does that affect people who spend much of the day with a phone pressed against their ear? At this time, there isn’t science to link health problems to cell phone use, the Centers for Disease Control and Prevention noted.
The most accurate studies follow people for decades, but large-scale cell phone use hasn’t been around that long.
“What we can safely say is that over a dozen studies in the literature — large studies, following patients for five to 10 years — have not shown any categorical evidence of increased risk of developing brain tumors with cell phone usage,” Mehta said.
“What about 20, 30 years of use? Obviously, we just don’t have the data for that.”
Right now, the most consistent health risk associated with cell phone use is distracted driving and car accidents, the National Cancer Institute noted.
2. Consuming aspartame causes brain tumors
The artificial sweetener has been used in sodas, chewing gum and other foods since the 1980s.
As it was tested, very large “mega” doses were fed to rodents — far greater than what any human would consume — as part of the research process, and some of the animals developed certain tumors, Mehta said, leading to rumors and concerns.
“But there’s no evidence that they actually developed brain tumors,” he said. “In humans, there’s absolutely no evidence that occurs.”
Aspartame is “one of the most exhaustively studied substances in the human food supply,” with more than 100 studies supporting its safety, the U.S. Food and Drug Administration noted.
3. Doctors know why brain tumors develop
Most of the time, the cause is a mystery, according the American Brain Tumor Association. The vast majority of glioblastomas occur randomly, for example.
It can be “just bad luck,” said Dr. Manish Sharma, a neurosurgeon at Mayo Clinic Health System in Mankato, Minnesota, who recently treated a 24-year-old woman who developed a golf-ball size benign brain tumor.
Some brain tumors are linked with genetic disorders, including neurofibromatosis, tuberous sclerosis, and Li-Fraumeni syndrome.
Unnecessary exposure to radiation, including excessive dental X-rays, can also increase the risk of developing tumors, Mehta said. “You have to weigh the risk versus the benefit,” he noted. “Sometimes the benefit of X-raying your teeth far outweighs anything else.”
4. Brain cancer is rare and usually occurs in adults
Brain tumors affect all ages, genders and ethnicities, with more than 700,000 Americans living with a brain tumor today, according the American Brain Tumor Association. Brain tumors are the second most common cancer among children 14 and younger.
5. The ketogenic diet can cure glioblastoma
No diet can cure glioblastoma, noted Dr. Shiao-Pei Weathers, a brain tumor specialist at The University of Texas MD Anderson Cancer Center.
“The idea that you can ‘starve’ glioblastoma through diet is a myth,” she wrote in response to online claims that the ultra low-carb, high-fat eating plan may have benefits for patients. “Glioblastoma patients need nutrients — including carbohydrates — to keep their bodies strong through treatment.”
Overall, studies show animals that are fed a “massively calorie restricted diet” age slower and develop fewer tumors in their bodies, but there’s no evidence that’s true in humans, Mehta noted. People would have to cut down their daily calorie consumption by more than 50% over their lifetimes to mimic this drastic eating plan, which would be almost impossible to achieve, he added.
6. Superfoods can prevent brain cancer
Foods high in antioxidants, including blueberries, beans and nuts, have been touted as promoting good health by helping combat free radical damage.
“But there’s no evidence that there’s a known superfood that actually protects individuals from developing tumors,” Mehta noted.
7. Cutting sugar from the diet can prevent brain tumors
Avoiding sugar is good for overall health, but it’s not going to stop a tumor from growing, Mehta said. Tumors are very efficient in obtaining their nutritional needs from the host — the human.
8. Benign brain tumors are not serious
Benign tumors in other parts of the body don’t pose that much risk, but that’s not the case when they develop in the brain.
“Because of the fact they’re growing, and compressing the brain and injuring the brain, they definitely have the potential to become very serious,” Mehta noted. They just take a longer time to become dangerous because they grow slower.
9. Once removed, a brain tumor doesn’t grow again
Unfortunately, that’s an “absolute myth,” Mehta said.
During brain surgery, it’s often impossible for doctors to know where the tumor ends and normal brain begins. Microscopic cells from the mass may infiltrate into the surrounding tissue and grow back with time. That’s why many patients undergo radiation or chemotherapy after their brain tumors are removed.
10. There’s no hope for brain tumor patients
There are more than 120 different types of primary brain tumors and — with the exception of glioblastoma — doctors have made “dramatic improvement in the outcome for many of these patients,” Mehta said.
Advances in surgical techniques, anesthesia, radiation therapy and targeted drugs mean surgery is safer, survival is longer and the quality of life is better for many brain tumor patients.[/quote]
https://www.today.com/today/amp/tdna161303
DIFFERENT STROKES FOR DIFFERENT FOLKS
Thanks Gary for presenting most all the possible realistic options out there (failure not being one of them) for NWBO shareholders.
I may not have had your medical experiences and insights, but your expressed views below are my own as well!:
My own would suggest that before the first regulator acted, NWBO will be worth substantially more, and then either a partnership, or a buyout will occur. In either event, the necessary funding will be in place to deal with whatever comes along, and the trials for DCVax-Direct will be fully funded.
For those who believe that BP can starve NWBO out if approval doesn't come on the initial approach, I do believe they will dilute further at substantially higher prices after top line results are out if a partnership doesn't appear to be coming to fruition, and that will give them the funds needed to get whatever needs to be done completed, including Direct trials.
Sandpiper re:
Amazing how Big Players play this
Short. And I thot I had cahoonas!
Priceless
Evaluate re:
Are you saying that all healthcare is available to all at no cost in the UK?? Free? No health insurance costs/premiums? No copays? No income taxes towards healthcare? How do healthcare providers get paid there?
Healthcare in England is mainly provided by England's public health service, the National Health Service, that provides healthcare to all permanent residents of the United Kingdom that is free at the point of use and paid for from general taxation.
Wikipedia › wiki › Healthcare_in_E...
Healthcare in England - Wikipedia
Thanks Iwasadiver for your candor and covering the bases here!
This excerpt reminded me of my interactions with many MS/PHd’s:
It’s exhausting (The daily setting in of another intimidating migraine like: BEYOND what even a lawyer might face IMHO)and in my practice and experience is often based more upon ego than on interdisciplinary compromise on treatments where that compromise would not even remotely put the patient in harm’s way. The nit picking over this antibiotic or that ventilator setting or how long the patient stays in the hospital is so overblown and unnecessary that the bickering itself is the actual thing that has the potential to harm patients.
I feel in DCVax’s case there will indeed be a separation of the arms in long term OS and a fairly clear PFS advantage to settle the nerves of the old guard. Either way, this intellectual masturbation will eventually be meaningless to Patients, the Physicians who treat them, and everyone other than the Stupps, the Wicks, and others like them that sit as “Chairmen” believing their purity is more pure than others
Big +15 mln Increase in Short Interest: re Shorting Against the Box": Nothing to do with done $400 mln offering.
What is a Short Sell Against the Box?
A short sell against the box is the act of short selling securities that you already own. This results in a neutral position where your gains in a stock are equal to the losses. For example, if you own 100 shares of ABC and you tell your broker to sell short 100 shares of ABC, you conducted a short sale against the box.
Understanding Short Sell Against the Box
A "short sell against the box" is also known as "shorting against the box." Sellers use this technique when they do not actually want to close out their position on a stock. The strategy is generally used by investors who believe the stock is due for a fall in price, but do not wish to sell because they believe the fall is temporary and the stock will rebound quickly.
Restrictions
The Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA) regulate when sellers are allowed to sell short. For instance, in February 2010, the SEC adopted the alternative uptick rule, which restricts short selling when a stock drops more than 10% in one day. In that situation, those engaging in a short sale (even if the shares are already owned) usually must open a margin account.
An alternative strategy is buying a put option,(What JL did) which gives investors the right, but not the obligation, to sell the shares. Buying a put option has a per-share cost associated with it, which is comparable to a short sale transaction.
{/quotehttps://www.investopedia.com/terms/s/sellagainstthebox.asp
DIFFERENT STROKES FOR DIFFERENT FOLKS
Another NEW RECORD High in Short Interest:
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
8/15/2019 6,231,807 296,488 21.018749
7/31/2019 5,813,041 554,773 10.478233
7/15/2019 5,236,358 682,283 7.674760
6/28/2019 4,057,301 892,490 4.546046
6/14/2019 4,132,319 286,591 14.418872
5/31/2019 4,182,308 520,125 8.040967
5/15/2019 4,647,019 372,532 12.474147
4/30/2019 4,925,533 328,341 15.001273
4/15/2019 4,912,843 330,565 14.861958
3/29/2019 4,821,344 561,555 8.585702
3/15/2019 4,906,260 464,449 10.563614
2/28/2019 5,040,864 167,839 30.033925
2/15/2019 5,092,904 248,149 20.523573
1/31/2019 5,270,975 110,885 47.535510
1/15/2019 5,294,791 246,484 21.481277
12/31/2018 5,132,444 513,470 9.995606
12/14/2018 5,542,513 186,519 29.715541
11/30/2018 5,542,897 150,113 36.924830
11/15/2018 5,744,717 160,815 35.722520
10/31/2018 5,783,150 426,886 13.547294
10/15/2018 5,553,619 220,507 25.185681
9/28/2018 5,765,630 363,517 15.860689
9/14/2018 5,689,444 180,832 31.462595
8/31/2018 5,740,454 183,845 31.224423
8/15/2018 5,814,264 287,331 20.235422
Example of Chemo damage to Brain Tumor Patient
Man Who Ditched Chemotherapy In Favour Of Cannabis Oil 'Essentially Cancer Free'
News
A man was left 'shaking like a leaf' after being told he was 'essentially cancer free', having ditched chemotherapy in favour of cannabis oil.
George Gannon, from Basingstoke, Hampshire, UK, was previously told he had 12 brain tumours and only months to live; however, both he and his doctor were left stunned by his latest MRI.
Mr Gannon says he is 'essentially cancer free'. Credit: Southern Daily Echo
The 30-year-old started using cannabis oil last December and stopped his chemotherapy in February. For three months he treated himself with just the oil and a subsequent MRI revealed his tumours had stopped growing.
Mr Gannon then resumed a lower dose of chemo in late April and his latest MRI earlier this month showed he had all but beaten the cancer.
Speaking to the Southern Daily Echo, he said: "It was quite surreal, I was shaking like a leaf. It was the best news we could have ever imagined.
"Back in December I was told I probably wouldn't survive. The doctor literally said it was the best day of his medical career. Now I'm 'essentially' cancer free in less than a year."
Mr Gannon was living in Ko Pha Ngan, Thailand, when he got the diagnosis, flying back to the UK days later. The NHS subsequently prescribed him with powerful chemotherapy tablets - but they only caused his health to deteriorate dramatically. ?
Mr Gannon said: "The medication I was being subscribed was literally destroying me. I looked like the poster person for cancer, I was so ill. It all got very dark.
"It felt as though the doctors assumed I didn't have long left and just kind of gave up. There were talks of me going into a hospice at one point."
Neither Mr Gannon or doctors could believe the results of his latest MRI. Credit: Southern Daily Echo
Unwilling to accept this fate, Mr Gannon and his girlfriend, Natalie, researched other methods of medication, ultimately paying £1,300 ($1,588) a month on cannabis oil, which he used three times a day.
Mr Gannon said: "I started to feel like a completely new person but I had no idea if I was well or not. I suddenly had more energy and was behaving like normal, I could tell something had shifted but I wasn't sure. ?
"The long-awaited MRI results simply blew the doctors minds, not to mention ours. In short, I am essentially cancer-free in less than a year and they want to write journals and all sorts."
While the miraculous turn around is clearly cause for celebration, Mr Gannon said he doesn't want to get too carried away.
He said: "When you have cancer, you never fully get rid of it. I don't want to hype it up too much but it's more than obvious cannabis oil works well. I mean, it's cleared 12 tumours in less than a year."?
According to Macmillan, more research needs to be done into the potential benefits of cannabis for people with cancer.
The charity's website reads: "It is still unclear whether using cannabis has any anti-cancer effects. But there is some evidence that the chemicals in cannabis might help with symptoms such as nausea and pain.
"But these studies have had mixed results when used in clinical trials. Because of the mixed results, the general feeling of experts is that there needs to be more research into the chemicals found in cannabis and their possible benefit."
FYI: DID my COMPLETE Due Diligence on Cognate BioSciences LT financier (NOT that of BlackRock for those flying off the handle posters!)
EW Healthcare Partners Raises Over $745 Million Fund 2a, issued 23-Aug-2019
The EW Healthcare Partners team includes a number of experienced healthcare executives who help identify, work with, and add value to our portfolio companies. The executives with pharmaceutical experience include:
Lamberto Andreotti, senior advisor and former Chairman of Bristol-Myers Squibb Company;
PROMOTIONS
EW also announced that with the closing of Fund 2 Evis Hursever was promoted from Partner to Managing Director in the London office
BTW I was exposed in my latter years as a professional to EW! in their formative years.
BIG Strategic pieces coming into play despite THE SILENCE and couch potatoes NON STOP Pissing and Moaning.
That's why having broad RELEVANT real world experience matters.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Thanks Jack2479!
IMHO we will see the FRUITS of that association!
DIFFERENT STROKES FOR DIFFERENT FOLKS
Kabunushi re:
Top Line Data & SNO Abstract etc etc
Sukus re:
Drug overdoses have been so rampant in this country. What did the FDA do under Gottlieb leadership? 40000 people died needlessly every year. That is almost like a population of a small city. Most of them who died are young. Did it break your heart? It broke my heart.
Who approves this opioid medicine? The FDA.
Didn't the FDA know this drug causes dependency? They know.
Why did they keep approving opioid pain killers if they know the side effects?
This new FDA under Dr Sharpless is charged to spearhead initiative to find alternative pain killers which are safer and to approve those antidotes that save those lives from opioid and Fentanyl overdose.
BIG Thanks to BOTH:SUKUS and HYPEROPIA on FDA Sharpless GBM Awareness Day( YouTube ONLY)
sukus for first discovering:
Hbpainter re:
Didn't DI state that the acting head was 'on our side,' sure I didn't imagine that!
My Plans at FDA
I am sure many of you would like to know specifically what I plan to do as Acting FDA Commissioner.
In the coming weeks, I will be highlighting some of my public health priorities, but let me make a few general points today.
First, I am a great admirer of Dr. Gottlieb. Scott and I had long discussions about much of the business before the FDA, and he gave me great advice.
There will of course be some letup from Gottlieb: for example, I don’t have nearly as interesting socks from a wardrobe POV.
On the plus side, I am pretty sure I can beat his time in the FDA 5K coming up this May 3 (since I am told he never ran it). In fact, I am planning on setting the Commissioner’s Record.
And let me dispel any misconceptions that the change in leadership reflects some desire of the President or the Secretary for the FDA to go in a different direction from the Gottlieb era.
That is not the case, Secretary Azar and the White House have been very clear with me that they have been impressed with the FDA’s efforts and would like to see this strong progress continue.
Moreover, there is great support for the FDA’s mission in Congress. This support is positive and bipartisan.
I’ve already experienced this first hand through a number of calls with key legislators and they’ve confirmed the high regard with which Congress holds the FDA.
So let me reassure you, I am not planning any radical changes from what the FDA has been trying to accomplish.
There are clearly a multi-fold number of near/at/in retirement investors vs that of 35 or under yrs of age
that is at MORE risk as young ones can make up for a total loss whereas the former group don’t have the luxury of another 30 plus years of “working”
Moreover the value of NWBO ‘s Intellectual Property Value based on solely what has already be disclosed on L trial unblinded results is worth more IMHO than its current stock market valuation.
DIFFERENT STROKES FOR DIFFERENT FOLKS
Iwasadiver re:
Re: JRIII Post# 240844
Golfing? Hahaha. You crack me up. I work 18 x 12 hours shifts/month in several ER's including a Level I Trauma Center and am a clinical professor of Emergency Medicine at a large Medical School. I'm a terrible golfer and don't have the time if I was good. Your false narratives about me is refreshing though. Keep up the good work old chap.
Friday, 06/07/19 03:04:52 PM
Re: maverick_1 post# 231976 0
Post # of 240857
Acting FDA Commissioner Sharpless Weighs in on RWE, Drug Pricing, and Talent
Quote:
In a speech, the U.S. Food and Drug Administration (FDA)acting Commissioner Ned Sharpless said that the agency is “open for business” in taking into consideration real-world evidence (RWE) for new cancer drugs.
“The FDA is always going to want to see really well-designed beautiful trials with convincing endpoints,” Sharpless said in his talk. “If you can do a large [randomized controlled trial] with overall survival as your outcome, there is nothing better.
”https://www.biospace.com/article/bio-roundup-agenu